LONDON (Alliance News) - Physiomics PLC on Monday said it has signed two further extensions to a Virtual Tumour project with an unnamed pharmaceuticals company first agreed in 2012.
The biology company said the sixth extension signed will cover predicting optimal regimens for follow-up compounds and in vitro to in vivo translation, while the seventh extension will predict optimal regimens for a candidate in an additional cancer indication.
No financial details were disclosed, but Physiomics said the project will be handled on a fee-for-service basis.
"We are very pleased to have further extended this collaboration, showing the value of our Virtual Tumour technology in supporting the development of follow-on compounds and indications. We hope this collaboration will continue well into the future," said Chief Executive Jim Millen.
Shares in Physiomics were up 6.7% to 0.04 pence early Monday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Physiomics (PYC)